Only 65% of those aged 15 to 24 at high risk of HIV accessed the treatment in 2024, compared with 81% of people aged 50 to 64.

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our ...

NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions. In a new guideline published ...

Targeted-release budesonide for treating primary IgA nephropathy TA937 20 December 2023 9 October 2025 ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

Suggested remit: To appraise the clinical and cost effectiveness of lecanemab within its marketing authorisation for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease.

Pregnant women at increased risk of pre-eclampsia at the booking appointment are offered a prescription of 75 mg to 150 mg of aspirin to take daily from 12 weeks until birth. Although this use is ...

This guideline covers recognising, assessing and treating post-traumatic stress disorder (PTSD) in children, young people and adults. It aims to improve quality of life by reducing symptoms of PTSD ...

NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...